AnaMar is a privately owned Swedish Biotech developing oral, first-in-class, peripherally acting, selective 5-HT2B receptor antagonists as a pan-antifibrotic treatment.

The company is operative in discovery and the early phases of drug development, from the idea stage to clinical trials. This includes invention and optimization of new drug candidates, evaluation of preclinical efficacy and safety and finally, confirmatory early clinical studies in patients with fibrotic disease.
AnaMar´s Candidate Drug AM1476 has entered early clinical development with systemic sclerosis as its first indication. The design of the currently ongoing Phase I development ensures relevance for all potential indications. The AnaMar compound portfolio has a strong IP composition of matter protection.